All Stories

Guest Post Robert Sutherland Smith GlaxoSmithKline’s cash flow gets dry rot; a bit of cash analysis

Tom Winnifrith
Saturday 1 June 2013

Robert Sutherland Smith is again proving that he is still alive with another guest post. Robert started his City career the year before I was born and is, I think, 157 years old. Fear not. He is very much alive and kicking. He and I have worked together for almost eight years at t1ps.com . He is my friend and he is a very funny and intelligent chap. He is now branching out to celebrate his 158th by doing some freelance writing over  at various places ( including Shareprophets.com naturally) on FTSE 350 Income stocks. Robert is a speaker at the UKInvestor Show on April 5th 2014. He is a great one for focussing on yield. RSS today looks at GlaxoSmithKline. RSS writes:

The latest information and news emerging from GlaxoSmithKline (GSK) is  of encouragement to investors generally but to dividend investors most  particularly. Although the company is one of the stock markets dividend yield  staple, with a long established reputation for cash generation, a glance at the  trends in its cash flow statements is a bit disconcerting. Whilst investment  spending over the last three years has been rising (that includes capital  expenditure) operating cash flow, the stuff that finances it (along with  dividend payments to ordinary shareholders) has been declining; and  significantly so, last year.

on TradingResearchPoint | Comments
About Tom Winnifrith
Bio
Tom Winnifrith is the editor of TomWinnifrith.com. When he is not harvesting olives in Greece, he is (planning to) raise goats in Wales.
Twitter
@TomWinnifrith
Email
[email protected]
Recently Featured on ShareProphets
Sign up for my weekly newsletter








Required Reading

Recent Comments


I also read